Drug Profile
CXS 299
Alternative Names: CXS-299; DACH-Ac-Pt (IV); DACH-acetato-Pt; DAPLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer ChemGenex Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action DNA inhibitors; Mitosis inhibitors; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 02 Feb 2009 Suspended - Preclinical for Cancer in Australia (unspecified route)
- 14 Jun 2007 Preclinical development is ongoing
- 11 Feb 2005 Preclinical trials in Cancer in Australia (unspecified route)